29Jul 2023
FDA Approves First Treatment Of Demodex Blepharitis

FDA Approves First Treatment Of Demodex Blepharitis

The FDA has approved lotilaner ophthalmic solution 0.25% (Xdemvy), the first specific treatment for Demodex blepharitis. Demodex mites infest eyelash hair follicles, leading to eyelid inflammation. The CEO of Tarsus, The FDA's decision is based on successful trials involving 833 patients, demonstrating significant improvement in eyelids and eradication of mites. Xdemvy proved generally safe, with mild adverse effects. Demodex blepharitis affects 1 in 12 adults in the US, often misdiagnosed, causing discomfort and eye damage.

  • #family health

Like

Save

Share